Key facts
- Corsera Health’s last known valuation is $186.0M (Nov 2025).
- It has raised $91.5M; the latest was Early Stage VC ($80.0M) in Nov 2025.
- Notable investors include The Invus Group, Forbion, J.M.M. Investments, Ellison Institute of Technology Oxford, Population Health Partners — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Corsera Health
- ·The full record, as it builds
Funding rounds
No funding rounds for Corsera Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Corsera Health
Developer of a cardiovascular health platform designed to predict and prevent atherosclerotic cardiovascular disease through early intervention. The company offers an artificial intelligence-based risk assessment tool, a once-annual RNAi medicine targeting PCSK9 and angiotensinogen, enabling patients to reduce exposure to cholesterol and blood pressure, extend health span, and avoid cumulative cardiovascular damage.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2024
- Website
- corserahealth.com/
- Ownership
- Privately Held (backing)
Corsera Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Corsera Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Corsera Health in its N-PORT filings yet. We sweep new filings monthly.